eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2012
vol. 16
 
Share:
Share:
abstract:
Case report

Thrombocytosis in Patients with Pancreatic Cancer Treated with Gemcitabine

Anna Świeboda-Sadlej
,
Leszek Kraj
,
Joanna Krawczyk
,
Ewa Nita
,
Jadwiga Dwilewicz-Trojaczek

Wspolczesna Onkol 2012; 16 (4): 353–355
Online publish date: 2012/09/29
View full text Get citation
 
PlumX metrics:
Gemcitabine is a cytostatic drug from the pyrimidine antimetabolite group. It is used in treatment of some neoplasms, among them inoperable pancreatic cancer. The most common undesirable effects of gemcitabine include pancytopenia, with thrombocytopenia associated with gemcitabine’s myelosuppressive activity. This study contains a description of six cases of patients with pancreatic cancer treated with gemcitabine, who – contrary to expectations – showed increased levels of thrombocytes. The number of thrombocytes ranged from 424 to 1059 x 109 (mean 470 x 109). It was highest during the 2nd and 3rd chemotherapy cycles and it normalized after completion of treatment. One patient suffered from a cardiac infarction on the 15th day of the 3rd cycle of treatment, despite a normal level of thrombocytes on the day; however, the patient indicated thrombocytosis on the 1st day of the cycle. No thromboembolic complications were observed in the remaining patients. These patients were not subjected to any antithrombotic prophylaxis. The mechanism by which thrombocytosis occurs after administration of gemcitabine and the clinical significance of this fact remain unknown.
keywords:

pancreatic cancer, thrombocytosis, gemcitabine, thrombosis

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.